Digital Twins for Precision Medicine and Drug Discovery
References
- De Domenico M, Arenas A, Bassett DS, et al. Challenges and opportunities for digital twins in precision medicine from a complex systems perspective. NPJ Digit Med. 2025;8:37. doi:10.1038/s41746-025-00337-x
- Gevaert O, Sadée C, Nagaraj D, et al. Medical digital twins: enabling precision medicine and medical artificial intelligence. Lancet Digit Health. 2025;7(7):e499–e511. doi:10.1016/S2589-7500(25)00028-7
- Saratkar SY, Shinde SK, Tiwari RK, et al. Digital twin for personalized medicine development. Front Digit Health. 2025;7:1583466. doi:10.3389/fdgth.2025.1583466
- Vallée A. Digital twins for personalized medicine require epidemiological data and mathematical modeling: viewpoint. J Med Internet Res. 2025;27:e72411. doi:10.2196/72411
- Sel K, Heltemes L, Jafari R, et al. Survey and perspective on verification, validation, and uncertainty quantification of digital twins for precision medicine. NPJ Digit Med. 2025;8:40. doi:10.1038/s41746-025-00340-4
- Lammert J, Lauss M, Harbst K, et al. Large language models-enabled digital twins for precision medicine in rare gynecological tumors. NPJ Digit Med. 2025;8:420. doi:10.1038/s41746-025-00420-0
- Baião AR, Treveil A, Barros RL, et al. A technical review of multi-omics data integration methods: from classical statistical to deep generative approaches. Brief Bioinform. 2025;26(4):bbaf355. doi:10.1093/bib/bbaf355
- Yetgin E. Revolutionizing multi-omics analysis with artificial intelligence and data processing. Quant Biol. 2025;13:e70002. doi:10.1002/qub2.70002
- Lin M, Chen Z, Hu J, et al. Machine learning and multi-omics integration: advancing cardiovascular translational research and clinical practice. J Transl Med. 2025;23:388. doi:10.1186/s12967-025-03888-0
- Wu Y, Xie L. AI-driven multi-omics integration for multi-scale predictive modeling of genotype-environment-phenotype relationships. Comput Struct Biotechnol J. 2025;27:265–277. doi:10.1016/j.csbj.2025.01.024
- Nam Y, Kim J, Park S, et al. Harnessing artificial intelligence in multimodal omics data integration: paving the path for the next frontier in precision medicine. Annu Rev Biomed Data Sci. 2025;7:225–250. doi:10.1146/annurev-biodatasci-102523-103801
- Cunha A, Carlisle B, Bhatt DL, et al. Flexynesis: a deep learning toolkit for bulk multi-omics data integration for precision oncology and beyond. Nat Commun. 2025;16:8261. doi:10.1038/s41467-025-08261-0
- Ge S, Chen J, Wan L, et al. Multi-omics single-cell data alignment and integration with enhanced contrastive learning and differential attention mechanism. Bioinformatics. 2025;41(8):btaf443. doi:10.1093/bioinformatics/btaf443
- Wang S, Liu X, Zhang Y, et al. Integrative multi-omics and machine learning reveal critical functions of proliferating cells in prognosis and personalized treatment of lung adenocarcinoma. NPJ Precis Oncol. 2025;9:243. doi:10.1038/s41698-025-0243-1
- Spooner A, Sowmya A, Sachdev PS, et al. Benchmarking ensemble machine learning algorithms for multi-class, multi-omics data integration in clinical outcome prediction. Brief Bioinform. 2025;26(2):bbaf116. doi:10.1093/bib/bbaf116
- Tai KH, Buczak P, Brun J, et al. Key concepts in clinical epidemiology: FAIRification of biomedical research data. J Clin Epidemiol. 2025;187:111920. doi:10.1016/j.jclinepi.2025.111920
- Dharmasivam M, Bhatt S, Walczak K, et al. Leading AI-driven drug discovery platforms: 2025 landscape and global outlook. Pharmacol Rev. 2025;77:100102. doi:10.1016/j.pharmrev.2025.100102
- Chakraborty C, Bhattacharya M, Chopra H, et al. Generative AI in drug discovery and development: the next revolution of drug discovery and development would be directed by generative AI. Ann Med Surg (Lond). 2024;86:6340–6343. doi:10.1016/j.amsu.2024.08.014
- Filella -Merce I, García-Jimeno S, Majewski M, et al. Optimizing drug design by merging generative AI with physics-based active learning framework. Commun Chem. 2025;8:238. doi:10.1038/s42004-025-01635-7
- Niazi SK. Artificial intelligence in small-molecule drug discovery: a critical review of methods, applications, and real-world outcomes. Pharmaceuticals (Basel). 2025;18(9):1271. doi:10.3390/ph18091271
- Ocaña A, Montero JC, Vera-Badillo FE, et al. Integrating artificial intelligence in drug discovery and early drug development: a transformative approach. Biomark Res. 2025;13:45. doi:10.1186/s40364-025-0045-x
- Qiao N, Chen Y, Bhatt DL, et al. The evolution of systems biology and systems medicine: from mechanistic models to uncertainty quantification. Annu Rev Biomed Eng. 2025;27:425–448. doi:10.1146/annurev-bioeng-030525-110045
- Yang Y, Chen Z, Liu X, et al. Spatial integration of multi-omics single-cell data with SIMO. Nat Commun. 2025;16:1265. doi:10.1038/s41467-025-56523-4
- Sui X, Zhang L, Wang Q, et al. Scalable spatial single-cell transcriptomics and translatomics in 3D thick tissue blocks. Nat Methods. 2025. doi:10.1038/s41592-025-02867-0
- Duan J, Li H, Zhao X, et al. Single-cell multi-omics and spatial transcriptomics reveal the transcriptional regulatory landscape of clear cell renal cell carcinoma. Transl Androl Urol. 2025;14(10):2953–2974. doi:10.21037/tau-25-1053
- Ge S, Wang Y, Liu J, et al. Deep learning in single-cell and spatial transcriptomics data analysis: advances and challenges from a data science perspective. Brief Bioinform. 2025;26(2):bbaf136. doi:10.1093/bib/bbaf136
- Loach M, Bacon W, Bray S, et al. Galaxy single-cell & spatial omics community update: navigating new frontiers in 2025. Cell Genomics. 2025;5(10):101005. doi:10.1016/j. xgen.2025.101005
- Malhotra Y, Singh A, Patel R, et al. Advancements in protein structure prediction: AlphaFold comparative overview. Comput Biol Med. 2025;188:109842. doi:10.1016/j.compbiomed.2025.109842
- Rennie ML, Oliver MR. Emerging frontiers in protein structure prediction following the AlphaFold revolution. J R Soc Interface. 2025;22(225):20240886. doi:10.1098/rsif.2024.0886
- Madaminov F. Regulating the use of AI in drug development: legal challenges and compliance strategies. Food Drug Law J. 2025. Available from: https://www.fdli.org/2025/07/regulating-the-use-of-ai-in-drug-development-legal-challenges-and-compliance-strategies/
- You JG, Park J, Kim S, et al. Clinical trials informed framework for real world clinical implementation of AI. NPJ Digit Med. 2025;8:107. doi:10.1038/s41746-025-00893-2
- Marbán -González A, Gómez-Tamayo JC, Cordomi A. Exploiting PubChem and other public databases for virtual screening in 2025: what are the latest trends? Expert Opin Drug Discov. 2025;20(11):1387–1403. doi:10.1080/17460441.2025.2558161
- Verma VV, Singh S, Sharma P, Kumar A. A comprehensive review on structural insights through molecular visualization: tools, applications, and limitations. J Mol Model. 2025;31(6):173. doi:10.1007/s00894-025-06402-y
- Neovarsity. How cheminformatics is used in drug discovery in 2025? Published March 17, 2025. Accessed December 8, 2025. Available from: https://neovarsity.org/blogs/how-cheminformatics-is-used-in-drug-discovery
- Neovarsity. Top 9 applications of cheminformatics in the biopharma industry [2025]. Published March 6, 2025. Accessed December 8, 2025. Available from: https://neovarsity.org/blogs/cheminformatics-applications-biopharma-2025
- IntuitionLabs. A comparative analysis of cheminformatics platforms. Published September 27, 2025.Accessed December 8, 2025. Available from: https://intuitionlabs.ai/articles/cheminformatics-platforms-comparison
- Drug Discovery News. The power of structure-based drug design. Published August 20, 2025. Accessed December 8, 2025. Available from: https://www.drugdiscoverynews.com/structure-based-drug-design-15997
- Almagro D, Martínez-Jiménez F, López-Bigas N. Assessing molecular docking tools: understanding drug discovery and design. Future J Pharm Sci. 2025;11:33. doi:10.1186/s43094-025-00862-y
- Baaden M, Glowacki DR. Virtual reality in drug design: benefits, applications and perspectives. Curr Opin Struct Biol. 2025;92:103044. doi:10.1016/j.sbi.2025.103044
- Deepmirror. Top drug discovery software solutions to watch in 2025. Accessed December 8, 2025. Available from: https://www.deepmirror.ai/post/top-drug-discovery-software-solutions-to-watch-in-2025
- Verma VV, Singh S, Sharma P, Kumar A. A comprehensive review on structural insights through molecular visualization: tools, applications, and limitations. J Mol Model. 2025;31(6):173. doi:10.1007/s00894-025-06402-y
- Takeda S, Kanai S, Tsuda K, Ohta M, Tokiwa H. AI-driven synthetic route design incorporated with retrosynthesis knowledge. J Chem Inf Model. 2022;62(3):1166–1175. doi:10.1021/acs.jcim.1c01074
- ChemCopilot. AI retrosynthesis tools: revolutionizing organic chemistry and drug discovery. Published April 23, 2025. Accessed December 8, 2025. Available from: https://www.chemcopilot.com/blog/ai-retrosynthesis-tools-revolutionizing-organic-chemistry-and-drug-discovery
- Schomburg L, Häse F, Roch LM, Aspuru-Guzik A. Accelerating compound synthesis in drug discovery: the role of digitalisation and automation. Chem Soc Rev. 2025. doi:10.1039/D5CS00678C
- MedChemExpress. AI as the new drug discovery accelerator: how it’s reshaping the future of medicine. Published December 2025. Accessed December 8, 2025. Available from: https://medium.com/@medchemexpress_llc/ai-as-the-new-drug-discovery-accelerator
- Marbán -González A, Gómez-Tamayo JC, Cordomi A. Exploiting PubChem and other public databases for virtual screening in 2025: what are the latest trends? Expert Opin Drug Discov. 2025;20(11):1387–1403. doi:10.1080/17460441.2025.2558161
- Türková A, Zdrazil B. A ligand-based computational drug repurposing pipeline using KNIME and programmatic data access. J Cheminform. 2020;12:71. doi:10.1186/s13321-020-00474-z
- Sydow D, Burggraaff L, Szengel A, et al. Democratizing cheminformatics: interpretable chemical grouping using an automated KNIME workflow. J Cheminform. 2024;16:68. doi:10.1186/s13321-024-00894-1
- Ramírez -Márquez CD, Medina-Franco JL. Exploring chemical databases with KNIME. Low Code Data Sci. Published 2025. Accessed December 8, 2025. Available from: https://medium.com/low-code-for-advanced-data-science/exploring-chemical-databases-with-knime
- IntuitionLabs. A comparative analysis of cheminformatics platforms. Published September 27, 2025. Accessed December 8, 2025. Available from: https://intuitionlabs.ai/articles/cheminformatics-platforms-comparison
- Irwin JJ, Tang KG, Young J, et al. ZINC20—a free ultralarge-scale chemical database for ligand discovery. J Chem Inf Model. 2020;60(12):6065–6073. doi:10.1021/acs.jcim.0c00675
- Rácz A, Mihalovits LM, Beckers M, et al. The changing landscape of medicinal chemistry optimization. Nat Rev Drug Discov. 2025;24(11):870–887. doi:10.1038/s41573-025-01225-1
- Beckers M, Stiefl N, Fechner N, Sirockin F. 25 years of small-molecule optimization at Novartis: a retrospective analysis of chemical series evolution. J Chem Inf Model. 2025;65(4):1523–1538. doi:10.1021/acs.jcim.2c00785
- Niazi SK. Artificial intelligence in small-molecule drug discovery: a critical review of methods, applications, and real-world outcomes. Pharmaceuticals (Basel). 2025;18(9):1271. doi:10.3390/ph18091271
- Kombo DC, LaMarche MJ. The logic of chemical optimization. J Med Chem. 2025;68(11):11572–11585. doi:10.1021/acs.jmedchem.5c00445
- Yung-Chi C, Prusoff WH. Structural simplification: an efficient strategy in lead optimization. Acta Pharm Sin B. 2019;9(6):1104–1119. doi:10.1016/j.apsb.2019.06.008
- Heinzke AL, Pahl A, Zdrazil B, et al. Occurrence of “natural selection” in successful small molecule drug discovery. J Med Chem. 2024;67(13):11226–11241. doi:10.1021/acs. jmedchem.4c00811
- Kelley NW, Bhatt S, Walczak P, et al. Diffusion models at the drug discovery frontier: a review on generating small molecules versus therapeutic peptides. Biology (Basel). 2025;14(12):1665. doi:10.3390/biology14121665
- Shurtleff VW, Layton ME, Parish CA, et al. Accelerating the hit-to-lead optimization of a SARS-CoV-2 Mpro inhibitor series by combining high-throughput medicinal chemistry and computational simulations. J Med Chem. 2025;68(8):8269–8294. doi:10.1021/acs.jmedchem.4c02941
- Roche P, Varnek A, Morelli X. Integrated strategy for lead optimization based on fragment growing: the diversity-oriented-target-focused-synthesis approach. J Med Chem. 2018;61(14):6315–6330. doi:10.1021/acs.jmedchem.8b00653
- Atz K, Böcker J, Gabernet G, et al. Expediting hit-to-lead progression in drug discovery through reaction prediction and multi-dimensional optimization. Nat Commun. 2025;16:1005. doi:10.1038/s41467-025-66324-4
- Kuentz M, Holm R, Elder DP. Dose number as a tool to guide lead optimization for orally bioavailable compounds in drug discovery. J Med Chem. 2022;65(18):12138–12151. doi:10.1021/acs.jmedchem.1c01687
- Quinn -Bohmann N, Wilmanski T, Sarmiento KR, et al. Microbial community-scale metabolic modelling predicts personalized short-chain fatty acid production profiles in the human gut. Nat Microbiol. 2024;9:2300–2313. doi:10.1038/s41564-024-01728-4
- Sizemore N, Oliphant K, Zheng R, Martin CR, Claud EC, Chattopadhyay I. A digital twin of the infant micro-biome to predict neurodevelopmental deficits. Sci Adv. 2024;10(15):eadj0400. doi:10.1126/sciadv.adj0400
- Caenepeel C, Falony G, Machiels K, et al. Dysbiosis and associated stool features improve prediction of response to biological therapy in inflammatory bowel disease. Gastroenterology. 2024;166(3):483–495. doi:10.1053/j.gastro.2023.11.304
- Stein -Thoeringer CK, Saini NY, Zamir E, et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immuno-therapy. Nat Med. 2023;29:906–916. doi:10.1038/s41591-023-02234-6
- Khan T, de Koning K, Endresen D, et al. TwinEco: a unified framework for dynamic data-driven digital twins in ecology. Ecol Inform. 2025;91:103407. doi:10.1016/j. ecoinf.2025.103407
- Rehman SSU, Nasar MI, Mesquita CS, et al. Integrative systems biology approaches for analyzing microbiome dysbiosis and species interactions. Brief Bioinform. 2025;26(4):bbaf323. doi:10.1093/bib/bbaf323
- Moysidou CM, van Niekerk DC, Stoeger V, et al. Modelling human gut-microbiome interactions in a 3D bioelectronic platform. Small Sci. 2024;4:2300349. doi:10.1002/smsc.202300349
- Ratiner K, Ciocan D, Abdeen SK, et al. Utilization of the microbiome in personalized medicine. Nat Rev Microbiol. 2024;22:291–308. doi:10.1038/s41579-023-00998-9
- Prins FM, Hidding IJ, Klaassen MAY, et al. Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease. Gut Microbes. 2024;16(1):2391505. doi:10.1080/194 90976.2024.2391505
- Bethlehem L, Estevinho MM, Grinspan A, et al. Microbiota therapeutics for inflammatory bowel disease: the way forward. Lancet Gastroenterol Hepatol. 2024;9(5):476–486. doi:10.1016/S2468-1253(24)00006-8
- Bucci V, Tzen B, Li N, et al. MDSINE: microbial dynamical systems INference engine for microbiome time-series analyses. Genome Biol. 2016;17(1):121. doi:10.1186/s13059-016-0980-6
DOI: https://doi.org/10.2478/ebtj-2026-0011 | Journal eISSN: 2564-615X
Language: English
Page range: 155 - 170
Published on: Jul 23, 2026
Published by: European Biotechnology Thematic Network Association
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Kosi Gramatikoff, Ed Judge, Ted Slater, Ljubica Milovic, Andrian Minchev, Miroslav Karabaliev, published by European Biotechnology Thematic Network Association
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.